All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Overall survival with intravenous platinum (i.e. mortality/number of participants deceased) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer who have febrile neutropenia
Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Mortality (in‐hospital death and 30‐day mortality) · adults receiving intravenous fluids whilst undergoing any form of surgery
Buffered showed no clear difference in mortality (in‐hospital death and 30‐day mortality) compared with non‐buffered crystalloid intravenous fluid (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
All‐cause mortality · patients with intravenous administration set replacement
Primary analysis: less may leads to higher mortality compared with more frequent (low certainty).
1 finding from 1 review
All‐cause mortality rate at 30 days · adults having abdominal surgery
Epidural analgesia showed no clear difference in all‐cause mortality rate at 30 days compared with intravenous patient‐controlled analgesia (low certainty).
1 finding from 1 review
30‐Day mortality · patients with < 30 days' limb ischaemiaa
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether cyclosporin changes disease‐specific mortality (time to compared with intravenous immunoglobulin (IVIG) (very low certainty).
1 finding from 1 review
Mortality within the longest · adults receiving intravenous fluids while undergoing major non‐cardiac surgery
It is very uncertain whether perioperative restrictive fluid therapy changes all‐cause mortality (during longest compared with goal‐directed fluid therapy (very low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Mortality at 30 days
It is very uncertain whether summary of findings TIVA changes mortality At 30 days compared with inhalational maintenance of anaesthesia (very low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in mortality (all infants): 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review